I am working with a colleague that is interested in medication error trends during the COVID 19 pandemic. Below is a summary of the research and a link to a survey. It takes about 15 minutes to complete and contains 6 questions. Completely voluntary participation.

Curious how pump programming is being built for this combination product. For the bamlanivimab 700 mg, etesevimab 1400 mg are you:

-listing the mg for 1 of the agents and having a clinical alert indicating it is a combination product with both mg strengths?
-listing the total mg (i.e. 2100 mg) with a clinical alert indicating individual monoclonal antibody strengths?
-Other alternate build (please elaborate)

Thank you so much for any insight into your practices you can provide.

Looking at the info provided by Lilly:

Preparation and Administration
• The 700 mg dose MUST BE prepared using 0.9% sodium chloride.
• Preparation of 700 mg dose of bamlanivimab for IV infusion*
• Administration of a dose of 700 mg of bamlanivimab in an IV infusion*
• Bamlanivimab solution for infusion should be prepared by a qualified health care professional using aseptic technique.

Has anyone noticed COVID patients requiring higher than usual doses of neuromuscular blockers on ventilators? We have had several patients maxed out on cisatricurium and still over-breathing the vent...

thanks!